Cardiosense is a digital biomarker platform that provides multi-sensor devices and proprietary algorithms to detect early signs of diseases.
Cardiosense has raised $15.1M in total funding. The most recent round was Series A. The last funding was announced in December 2022.
Cardiosense's investors include Hatteras Venture Partners, Portal Innovations, OSF Ventures, Laerdal Million Lives Fund, UnityPoint Health Ventures.
Cardiosense is headquartered in Chicago, United States.
Cardiosense is a digital biomarker platform that provides multi-sensor devices and proprietary algorithms to detect early signs of diseases.
Cardiosense is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cardiosense — Funding & Investors." VCBacked, December 8, 2022, https://www.vcbacked.co/company/cardiosense. Accessed August 14, 2026.
VCBacked. (2022). Cardiosense — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/cardiosense
{{cite web |title=Cardiosense — Funding & Investors |url=https://www.vcbacked.co/company/cardiosense |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated